Openbookopenbook
Equity
ESALF
+0.0 · +0.00%
USD · PINK

Eisai Co. Ltd(ESALF) Stock Analysis | Healthcare

USD --+0.00%
Reward39Moderate
Risk29Low
75%Data
3.3% dividend yield
Defensive Anchor
Market Cap:9.35Bn
ⓘ
Reward Rating
39
Moderate
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
29
Low
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ESALF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ESALF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $75.99.

What is Eisai Co. Ltd?

engages in the research and development, manufacture, sale, and import and export of pharmaceuticals.

ESALF · Verdict

Limited reward · low risk

ESALF stands out on balance sheet and volatility, but watch the growth signal.

Based on 88% data coverage

ESALF · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet79/100

    Interest covered 18.4×

  • Volatility75/100

    Above average

Watchouts 2

  • Growth29/100

    Rev +1.4% CAGR · earnings -1.1%

  • Profitability38/100

    6% net margin · 5% ROE

Model-based scoring. For information only — not financial advice.

What is Eisai Co. Ltd?

engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. In addition, the company focuses on neurology and oncology and therapeutic areas. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 9.35B, and a P/E ratio of 29.2x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (39)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

IPSEFMid Cap / 9.3B market cap
Ipsen S.A
Compare
KYKOFMid Cap / 9.6B market cap
Kyowa Kirin Co. Ltd
Compare
SFOSFMid Cap / 9.8B market cap
Shanghai Fosun Pharmaceutical (Group) Co. Ltd
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap9.35B
P/E Ratio29.2035
Dividend Yield3.29%
Beta-0.275
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.